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OBJECTIVE — Hemeoxygenase(HO)leadstothegenerationoffreeiron,carbonmonoxide,
and bilirubin. A length polymorphism of GT repeats in the promoter of human HO-1 gene has
been shown to modulate gene transcription. The aim of this study was to assess the association
of the length of (GT)n repeats in the HO-1 gene promoter with serum bilirubin, markers of iron
status, and the development of coronary artery disease (CAD).
RESEARCH DESIGN AND METHODS — We screened the allelic frequencies of (GT)n
repeats in the HO-1 gene promoter in 986 unrelated individuals who underwent coronary
angiography. Serum bilirubin and markers of iron status were evaluated.
RESULTS — The distribution of numbers of (GT)n repeats was divided into two subclasses:
class S included shorter (27) repeats, and class L included longer (27) repeats. Among those
with diabetes, subjects with the L/L genotype had signiﬁcantly lower bilirubin levels than those
with S/S and S/L genotypes (0.70  0.22 vs. 0.81  0.24 mg/dl, P  0.001) and higher serum
ferritin values (4.76  0.72 vs. 4.28  1.05 g/l for log ferritin, P  0.001). Compared with
those carrying the S allele, diabetic subjects with the L/L genotype had an almost threefold
increase in CAD risk after controlling for conventional risk factors (odds ratio 2.81, [95% CI
1.22–6.47], P  0.015). With adjustment for both serum bilirubin and ferritin, the effect of
HO-1 promoter polymorphism on susceptibility to CAD disappeared.
CONCLUSIONS — Length polymorphism in the HO-1 gene promoter is correlated with
susceptibilitytoCADindiabeticpatients,andthiseffectmightbeconveyedthroughitsinﬂuence
on serum bilirubin and ferritin.
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H
eme oxidase (HO) is a rate-limiting
enzyme in heme degradation that
leads to the generation of free iron,
biliverdin, and carbon monoxide. Biliver-
dinissubsequentlyconvertedtobilirubin
via the action of biliverdin reductase, and
free iron is promptly sequestered into fer-
ritin. There are two genetically distinct
isozymes of HO: the inducible HO-1 and
a constitutively expressed HO-2. HO-1 is
a cytoprotective enzyme upregulated in
mammalsmostlydependentontranscrip-
tional activation of the HO-1 gene to di-
verse cellular stress.
The relationship of HO to atheroscle-
rotic vascular disease was suggested
initiallyin1994byanobservationalstudy
reporting that low serum concentrations
of bilirubin are associated with increased
risk of coronary artery disease (CAD) (1).
The human HO-1 gene has been mapped
tochromosome22q12,anda(GT)ndinu-
cleotide repeat has been identiﬁed in the
proximal promoter region (2). The (GT)n
repeat is highly polymorphic and modu-
lates gene transcription by oxidant
challenge (3). We and others have dem-
onstrated that a longer (GT)n repeat ex-
hibits lower transcriptional activity and is
associated with susceptibility to CAD in
high-risk patients (4,5).
Bilirubin, a natural product of heme
catabolismbyHO,hasbeenrecognizedto
be an antioxidant and can inhibit lipid
peroxidation (6). There is accumulating
evidence that individuals with high-
normalorjustgreaterthannormalplasma
bilirubin levels have a lesser incidence of
CAD and carotid plaque formation (7,8).
HO-1 is also of critical contribution to
iron homeostasis. The association be-
tweenbodyironstatusandtheriskofcar-
diovasculardiseasewasﬁrstpostulatedby
Sullivan in the early 1980s (9) and there-
after by a number of epidemiological
studies (10). Because HO-1 promoter
polymorphism can conceivably affect the
development of CAD, in the present
study, the associations of the HO-1 pro-
moter polymorphism with bilirubin lev-
els, markers of iron status, and the
development of CAD were examined.
RESEARCH DESIGN AND
METHODS— The study population
consisted of 986 unrelated adult patients
who consecutively underwent coronary
angiographyintheCardiologyDivisionat
Taipei Veterans General Hospital from
August 1999 to October 2000. CAD was
documented by angiographic evidence of
75% stenosis of at least one major cor-
onary artery or a history of prior angio-
plasty, coronary artery bypass surgery, or
myocardialinfarctionbyhistoryvalidated
by electrocardiographic changes. The
non-CAD group consisted of subjects
who had normal coronary arteries as doc-
umented by angiography (20% intralu-
minal obstruction) and had neither a
history of atherosclerosis nor clinical or
laboratory evidence of atherosclerosis in
other vascular beds. This study protocol
was approved by the review committee of
Taipei Veterans General Hospital, and all
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consent.
Analysis of length variability of
(GT)n repeats in HO-1 gene
promoter
Genomic DNA was extracted from leuko-
cytes by the conventional procedure. The
5-ﬂanking region containing (GT)n re-
peats of the HO-1 gene was ampliﬁed by
PCRwithaFAM-labeledsenseprimer,5-
AGAGCCTGCAGCTTCTCAGA-3, and
an antisense primer, 5-ACAAAGTCTGG
CCATAGGAC-3, as described previ-
ously (4). The PCR products were mixed
together with a GenoType TAMRA DNA
ladder(sizerange50–500bp;GibcoBRL)
and analyzed with an automated DNA se-
quencer (ABI Prism 377). Each size of
the (GT)n repeat was calculated using
GeneScan Analysis software (PE Applied
Biosystems).
Baseline measurements
Hypertension was deﬁned as measured
systolic blood pressure 140 mmHg or
diastolic blood pressure 90 mmHg. Di-
abetes was diagnosed on the basis of the
World Health Organization criteria. Pa-
tients with hypercholesterolemia were
deﬁned as those having a total cholesterol
level of 240 mg/dl or those who were
receiving lipid-lowering therapy. Labora-
tory measurements were made on 12-h
fasting venous blood samples. The bio-
chemical indicators of iron status in this
study included the serum iron concentra-
tion, the serum ferritin levels, the serum
total iron-binding capacity (TIBC), and
the serum transferrin saturation. Serum
ironwasmeasuredwithacolorimetricas-
say. Serum ferritin and TIBC values were
assessed with an immunometric assay
(Boehringer Mannheim). Transferrin sat-
uration was calculated as the ratio of se-
rum iron to TIBC.
Statistical analysis
Allstatisticalanalyseswereconductedus-
ing the SPSS statistical package (version
10.0; SPSS, Chicago, IL). Distributions of
continuous variables in groups were ex-
pressed as means  SD and compared by
t test for two groups or ANOVA using the
least signiﬁcant difference method for
post hoc multivariate comparison of the
meansformorethanthreegroups.Values
ofserumferritinwerelogtransformedbe-
cause of their skewed distributions. Cate-
gorical variables were analyzed by 
2 test
or Fisher’s exact test. The association of
CAD status with the allele frequency was
assessed with consideration of confound-
ing effects by known coronary risk
factors, such as age, sex, diabetes, hyper-
cholesterolemia, hypertension, and
smoking habits. After preliminary bivari-
ate analysis using the t test and 
2 test,
multiple logistic regression analysis with
forwardstepwiseselectionwasperformed
to evaluate the effect of genotype on CAD
after controlling for other established risk
factorsofCAD.Signiﬁcancewasaccepted
at P  0.05. All of the study participants
were Chinese from northern Taiwan and
had similar ethnic backgrounds.
RESULTS— The allele frequencies of
(GT)n microsatellite polymorphism in the
HO-1 promoter region were highly poly-
morphic, ranging from 16 to 38 (4). Be-
cause the proportion of allele frequencies
of either 27 or 27 GT repeats was
50%, we classiﬁed the alleles into two
subgroups: the lower component, with
repeat number 27, was designated as
“class S,” and the upper component, with
27 GT repeats, was designated as “class
L.” These patients were then classiﬁed as
having an S/S, S/L, or L/L genotype ac-
cording to each of their HO-1 alleles.
Table 1 of the online appendix (avail-
able at http://dx.doi.org/10.2337/dc07-
2126) shows the distribution of HO-1
promoter genotypes in all subjects and in
those with hypertension (n  639), dia-
betes (n  263), or hypercholesterolemia
(n  179) and those who currently
smoked (n  260) stratiﬁed by the status
ofCAD.Nosigniﬁcantdifferenceingeno-
typic frequencies between the two groups
(CAD vs. non-CAD) in the whole study
population was observed. However, dia-
betes was found to have a signiﬁcant in-
teraction with genotypes: the proportions
of S/S, S/L, and L/L genotypes were 36.5,
47.6, and 15.9%, respectively, in diabetic
subjectswithoutCADand18.5,51.5,and
30.0%, respectively, in diabetic subjects
with CAD.
Thecharacteristicsofthewholestudy
population and subjects with diabetes
stratiﬁedbyHO-1genotypearepresented
in Table 1. Across the three genotypes,
only serum bilirubin and ferritin concen-
trations were signiﬁcantly different in
boththewholestudypopulationandsub-
jects with diabetes. There were no signif-
icant differences in age, sex, percentages
ofriskfactors,levelsofserumcholesterol,
triglycerides, fasting blood glucose, or
markers of iron status including serum
iron, TIBC, and transferrin saturation
values.
The mean serum bilirubin level was
higher in carriers of the S allele (0.85 
0.32 mg/dl) than in those with the L/L
genotype (0.79  0.25 mg/dl) (P 
0.013) in the whole study population,
and the difference was more pronounced
(0.81  0.24 vs. 0.70  0.22 mg/dl, P 
0.001) in subjects with diabetes. Serum
ferritin levels were highest in subjects
with the L/L genotype, intermediate in
thosewiththeS/Lgenotype,andlowestin
those with the S/S genotype in the whole
study population and in subjects with di-
abetes. When subjects with the L/L geno-
type and those carrying the S allele were
compared, the ferritin level was signiﬁ-
cantly higher in subjects with the L/L ge-
notype(12799or4.540.88g/lfor
log ferritin) than in carriers of the S allele
(114  107 or 4.33  0.98 g/l for log
ferritin) (P  0.008 for log ferritin) in the
whole study population. Among subjects
with diabetes, this difference was again
much greater (148  104 vs. 111  96
g/lforferritin,P0.031or4.760.72
vs. 4.28  1.05 for log ferritin, P 
0.001).
The baseline characteristics of the
wholestudypopulationandsubjectswith
diabetesstratiﬁedbythestatusofCADare
summarizedinTable2.Whenallsubjects
were considered, patients with CAD were
olderandhadahigherpercentageofmale
sex, higher fasting blood glucose and tri-
glyceride levels, and a lower HDL value
comparedwiththosewithoutCAD,asex-
pected. Serum bilirubin levels were sig-
niﬁcantly lower (0.81  0.30 vs. 0.87 
0.32 mg/dl, P  0.006) and a trend to-
ward a higher serum ferritin level was ob-
served in patients with CAD (126  124
vs. 110  95 g/l, P  0.061). There was
no difference in serum iron value, TIBC,
or transferrin saturation between subjects
with versus without CAD. On the other
hand, with respect to demographic char-
acteristics, the two groups of diabetic pa-
tients with versus without CAD only
differed in percentages of male sex. Dia-
betic patients with CAD had signiﬁcantly
lowerserumbilirubinlevels(0.760.23
vs. 0.86  0.32 mg/dl, P  0.040) and
higher serum ferritin levels (141  139
vs. 104  102 g/l or 4.54  1.01 vs.
4.16  1.10 g/l for log ferritin, P 
0.024 for log ferritin).
The relations between serum biliru-
bin and ferritin levels, HO-1 genotypes,
andCADareshowninFig.1.Amongsub-
jects with diabetes, serum bilirubin levels
Bilirubin, ferritin, and HO-1 gene polymorphism
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genotype were signiﬁcantly lower than
those in carriers of the S allele, regardless
of their CAD status, whereas differences
in serum bilirubin levels between carriers
of the L/L genotype with and without
CAD were not statistically signiﬁcant. On
the other hand, log ferritin values in pa-
tients with CAD who had the L/L geno-
type were signiﬁcantly higher than those
in carriers of the S allele with or without
CAD. Differences in log ferritin values
between patients with and without CAD
who had the L/L genotype, although
substantial,didnotreachstatisticalsignif-
icance. Differences in both serum biliru-
bin and ferritin levels in nondiabetic
subjects were much less prominent than
those in subjects with diabetes.
Wethenperformedmultivariateanal-
yses to further examine the links between
serum bilirubin and ferritin levels, HO-1
genotypes, and CAD in diabetic patients.
After we controlled for conventional risk
factors, carriers of the L/L genotype
showed signiﬁcantly enhanced suscepti-
bility to CAD compared with those carry-
ing the S allele, resulting in an odds ratio
(OR) of 2.81 (95% CI 1.22–6.47, P 
0.015)(Table3).Asanextstep,weinves-
Table 1—General characteristics of the study population stratiﬁed by HO-1 promoter genotypes
Genotype
P in all
subjects
P in
diabetic
subjects
S/S S/L L/L
All subjects
With
diabetes All subjects
With
diabetes All subjects
With
diabetes
n 221 60 489 133 276 79
Age (years) 70  86 9  86 8  10 68  96 9  96 8  9N S N S
Male sex (%) 90 87 89 85 88 80 NS NS
Hypertension (%) 68 78 65 66 64 73 NS NS
Current smoker (%) 34 28 28 26 29 29 NS NS
Fasting blood glucose (mg/dl) 109  36 148  45 112  46 155  65 110  44 151  62 NS NS
Total cholesterol (mg/dl) 192  42 187  43 187  35 180  35 189  36 188  40 NS NS
LDL cholesterol (mg/dl) 124  35 120  31 119  30 111  33 122  28 116  32 NS NS
HDL cholesterol (mg/dl) 40  11 37  11 39  11 36  94 0  11 40  15 NS NS
Serum triglycerides (mg/dl) 144  91 171  109 146  97 168  109 159  150 176  104 NS NS
Bilirubin (mg/dl)l 0.85  0.27 0.83  0.21 0.84  0.30 0.81  0.25 0.79  0.25 0.70  0.22 0.021 0.006
Serum iron (g/dl) 80  42 82  90 78  40 73  84 73  39 112  17 NS NS
Serum ferritin (g/l) 99  105 82  63 121  107 123  105 127  99 148  104 0.031 0.009
Log ferritin 4.19  0.95 4.10  0.87 4.40  0.98 4.36  1.12 4.54  0.88 4.76  0.72 0.003 0.008
TIBC (g/dl) 272  102 279  92 297  160 296  114 278  124 287  127 NS NS
Transferrin saturation (%) 27  17 27  17 27  13 23  16 25  15 24  17 NS NS
Data are expressed as means  SD unless indicated otherwise.
Table 2—Characteristics of the study population
Subjects without CAD Patients with CAD P
All subjects
With
diabetes All subjects
With
diabetes
CAD vs.
non-CAD in
all subjects
CAD vs.
non-CAD in
diabetes
n 322 63 664 200
Age (years) 67  10 68  96 9  96 8  9 0.002 NS
Male sex (%) 82 71 92 88 0.001 0.009
Hypertension (%) 63 78 66 68 NS NS
Current smoker (%) 26 25 31 29 NS NS
Fasting blood glucose (mg/dl) 104  34 147  47 114  47 154  63 0.001 NS
Total cholesterol (mg/dl) 187  35 184  33 190  38 184  40 NS NS
LDL cholesterol (mg/dl) 118  26 111  26 122  33 115  34 NS NS
HDL cholesterol (mg/dl) 42  11 38  12 39  11 37  11 0.001 NS
Serum triglycerides (mg/dl) 134  75 164  94 157  128 173  111 0.001 NS
Bilirubin (mg/dl)l 0.87  0.32 0.86  0.32 0.81  0.30 0.76  0.23 0.006 0.04
Serum iron (g/dl) 80  43 70  32 75  37 77  42 NS NS
Serum ferritin (g/l) 110  95 104  102 126  124 141  139 NS NS
Log ferritin 4.31  0.98 4.16  1.10 4.42  0.99 4.54  1.01 NS 0.024
TIBC (g/dl) 285  129 312  197 286  144 299  158 NS NS
Transferrin saturation (%) 30  14 26  12 28  12 28  12 NS NS
Data are expressed as means  SD; n  986.
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and ferritin levels with CAD separately.
When the HO-1 genotype was not in-
cluded in the model, a 0.1 mg/dl increase
in bilirubin levels decreased CAD risk by
16% and 1 log unit elevation in ferritin
values increased CAD risk by 41%. After
we included both the HO-1 promoter ge-
notype and bilirubin levels in the logistic
regression model, the OR of HO-1 effect
fell to 2.65 and became less signiﬁcant
(95% CI 1.05–6.69, P  0.040). When
both the HO-1 promoter genotype and
ferritin values were included, the OR of
HO-1 effect decreased to 2.31 and was of
borderline signiﬁcance (95% CI 0.97–
5.49, P  0.058). With adjustment of
both serum bilirubin and ferritin values,
the OR of HO-1 effect was reduced fur-
ther to 1.71 and became nonsigniﬁcant
(95%CI0.75–3.90,P0.203)(Table3).
CONCLUSIONS — Decreased HO-1
expression has been shown in humans
and experimental animals with diabetes
(11,12), and an inverse relationship be-
tween the HO-1 activity and vascular
complications associated with diabetes
was demonstrated (13). In line with these
ﬁndings, our previous study (4) revealed
that the length polymorphism in the
HO-1 gene promoter is correlated with
susceptibility to CAD in diabetic patients.
Figure1—SerumbilirubinandlogferritinlevelsaccordingtothreegenotypesandCADstatus.DataaremeansSD.*P0.05;**P0.01.DM,
diabetes.
Table 3—Association of HO-1 promoter genotypes with the risk of CAD among diabetic patients
OR (95% CI)
L/L vs. L/S 	 S/S Bilirubin (per 0.1 mg/dl) Log ferritin (per 1 unit)
Adjusted for traditional risk factors* 2.81 (1.22–6.47), P  0.015 0.84 (0.73–0.97), P  0.016 1.41 (1.04–1.89), P  0.025
Additionally adjusted for bilirubin 2.65 (1.05–6.69), P  0.040
Additionally adjusted for ferritin 2.31 (0.97–5.49), P  0.058
Additionally adjusted for both bilirubin
and ferritin
1.71 (0.75–3.90), P  0.203
*Adjusted for age, sex, history of hypertension, hypercholesterolemia, and smoking status.
Bilirubin, ferritin, and HO-1 gene polymorphism
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strated that this effect might be conveyed
through its inﬂuence on bilirubin and
ferritin.
The concept that HO-1 may be caus-
ally related to cardiovascular diseases in
humanshasbeensuggestedbystudiesas-
sessing the (GT)n dinucleotide length
polymorphism in the 5-ﬂanking se-
quence of the human HO-1 gene. By us-
ing HO-1 promoter/luciferase reporter
genes carrying different lengths of (GT)n
repeats, we demonstrated previously that
the more (GT)n repeats in the promoter
region, the less transcriptional activity of
the HO-1 gene in rat aortic smooth mus-
cle cells (4); a similar result was also
shown earlier in Hep3B cells (3).
Bilirubin is a natural product of heme
catabolismbyHO.Herewedemonstrated
that there is an association between HO-1
promoter polymorphism and serum bili-
rubinlevels,whicharecorrelatedwiththe
development of CAD. The mean serum
bilirubin level was signiﬁcantly higher in
carriers of the S allele than in those with
the L/L genotype. In a previous case-
control study of individuals with early fa-
milial CAD, higher serum bilirubin
concentrations within the normal range
were associated with a signiﬁcant and
marked reduction in CAD risk (7). In the
prospective Framingham Offspring
Study, higher serum bilirubin concentra-
tions were associated with a decreased in-
cidence of ischemic heart disease (8).
Considering the antioxidant and anti-
atherogenic properties of bilirubin, the
beneﬁcial inﬂuence on serum bilirubin in
carriers of the S allele might exert a pro-
tective effect against the development of
CAD.
HO releases free ferrous (Fe
2	) iron
from heme. The toxic effect of free iron
has been linked to oxidative stress
through the Fenton reaction, in which
Fe
2	 oxidizes H2O2, leading to the gen-
eration of hydroxyl radicals (14), which
in turn initiate lipid peroxidation. The
amount of free ferrous iron is normally
maintained at a very low level in humans.
Of all the iron in the body (4 g), approx-
imately two-thirds is found in association
with hemoglobin in the ferrous form, and
the majority of the remainder is stored as
ferritin. In 1981, Sullivan (9) suggested
that a state of iron depletion was poten-
tially protective against coronary heart
disease. Although the majority of animal
research and the in vitro human studies
support a role of iron in the pathogenesis
of atherosclerosis, prospective human
studieshaveprovidedinconsistentresults
in terms of clinical cardiovascular out-
comes (10). Some investigators have hy-
pothesized that iron may be primarily
involved in the early stage of atheroscle-
rosis, and focusing on cardiovascular
morbidity and mortality (reﬂecting later
stages of the disease) may not give insight
into the potential mechanistic role of iron
(15). Likewise, one recent study demon-
strated that reduction of body iron stores
by phlebotomy in patients with periph-
eralarterialdiseaseproducedasigniﬁcant
improvement in cardiovascular outcomes
in patients aged 60 years but not in
those at an older age (and thus with more
advanced atherosclerosis) (16).
Inthepresentstudy,fortheﬁrsttime,
we demonstrated that there is an associa-
tion between HO-1 promoter polymor-
phism and serum ferritin concentrations,
ameasureofthebody’sironstores,andan
association between ferritin concentra-
tions and the development of CAD in di-
abetic subjects. The mechanisms by
which HO-1 polymorphism confers the
variance in ferritin values remain to be
elucidated. Nevertheless, a few animal
studies and clinical data provided some
indirectclues.Amousemodeldeﬁcientin
mammalian HO-1 (Hmox1) developed
pathological accumulation of tissue iron
stores associated with an increase in se-
rum ferritin levels (17). HO-1 deﬁciency
is very rare in humans. The ﬁrst autopsy
case of HO-1 deﬁciency was a 6-year-old
boy who presented with growth retarda-
tion, anemia, elevated serum levels of fer-
ritin and heme, low serum bilirubin
concentrations, and hyperlipidemia.
Fatty streaks and ﬁbrous plaques were
noted in his aorta (18). Moreover, treat-
ment of healthy volunteers, patients with
primary biliary cirrhosis, and patients
with idiopathic hemochromatosis sub-
stantially with HO inhibitors increased
serum ferritin concentrations (19). We
hence postulated that the lower expres-
sionlevelofHO-1imposedbytheLallele
under higher oxidative stress, as in the
setting of diabetes, increases iron load in
the vascular system, which may contrib-
ute to the development of atherosclerosis
in such a virulent way.
The present study has strengths and
limitations. Strengths include the large
number of patients and the fact that all
subjects had coronary arteriography and
measures of bilirubin and ferritin. Fur-
thermore, the homogeneous ethnic back-
ground possibly reduces variability in
measurements. Among the study limita-
tions is that the sample is primarily Chi-
nese, making generalization to the other
ethic groups uncertain. Furthermore, the
present study design was cross-sectional,
and we cannot infer causality.
In summary, we have demonstrated
that the microsatellite polymorphism in
thepromoterofHO-1geneimposesmod-
ulation on serum bilirubin and ferritin
levels,whichmightbeassociatedwiththe
development of CAD among diabetic
subjects.
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